Assembly's line continues to sputter

Today's Big News

Apr 19, 2023

Forbion points to high investor demand in €1.3B raise for largest haul yet


Revolo drops dab of midphase data on would-be Dupixent rival


More Assembly required: Biotech looks for core inhibitor partnership in shift to antivirals


Metrodora opens neuroimmune research center in Salt Lake City, reveals first biotech partners

 

Featured

Forbion points to high investor demand in €1.3B raise for largest haul yet

If there’s a slowdown in VC investment, no one’s told Forbion. The European life sciences-focused growth fund has raised 1.35 billion euros ($1.5 billion) across two funds, marking the firm’s largest fundraising to date.
 

Top Stories

Revolo drops dab of midphase data on would-be Dupixent rival

Revolo Biotherapeutics thinks it has the data to keep advancing a would-be challenger to Dupixent. In a small, short phase 2a allergy trial, the biotech linked its peptide to a “numeric reduction” on the primary endpoint, emboldening it to start looking forward to further development.

More Assembly required: Biotech looks for core inhibitor partnership in shift to antivirals

Less than a month after Assembly paused the development of one of two core inhibitors to treat hepatitis B, the duo has now been put up for grabs.

Minimizing Barriers to eConsent Adoption

Michael Hughes, Chief Product Officer at YPrime discusses the benefits and challenges of eConsent implementation and how to circumvent the biggest barriers to adoption.

Metrodora opens neuroimmune research center in Salt Lake City, reveals first biotech partners

The Metrodora Institute has opened the doors of its medical and research center in Salt Lake City, giving biopharma companies a new neuroimmune drug development and clinical trial partner in Utah.

Headlands acquires Massachusetts trial site specializing in neurodegenerative diseases

Headlands Research, which manages trial sites in North America, has acquired a research site in Massachusetts that has specialized in neurodegenerative diseases for more than a quarter century.

J&J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma, leaked abstract shows

J&J and Legend's CAR-T therapy Carvykti slashed the risk of disease progression or death by a whopping 74% in multiple myeloma, according to a leaked abstract Fierce Pharma has obtained. The number exceeds analysts' expectations and puts Bristol Myers Squibb on notice.

Medtronic embarks on monthslong global layoffs, with total cuts unknown

With about 100,000 employees worldwide, the process of notifying people whether they still have a job could take months, the company said in a statement to Fierce Medtech.

HIMSS23: Google proceeds with caution in piloting its LLM in healthcare

CHICAGO—Google execs spoke with Fierce Healthcare at the 2023 Healthcare Information Management and Systems Society global conference about the tech giant's recent moves to bring AI and cloud technologies into healthcare, including its large language model and its new claims acceleration suite.

AbbVie's Qulipta gains edge on Pfizer's Nurtec with FDA approval to prevent chronic migraines

With an expanded indication to prevent chronic migraines, AbbVie's Qulipta scored an edge against migraine rival Nurtec ODT from Pfizer.

AACR: Adela’s multi-cancer blood test shows promise in detecting early stage tumors

Canadian newcomer Adela has shown that its test for detecting the faint traces of cancer in the bloodstream could spot 12 different types of the disease, including many in their early stages when they have the best chances of being treated.
 
Fierce podcasts

Don't miss an episode

'The Top Line': Which biotechs scored big VC dollars in 2022?

This week on "The Top Line," we talk about biotech’s top money raisers in 2022. We also cover J&J's talc litigation, prison plans for Elizabeth Holmes and more of this week's top headlines.

 

Resources

Research

Maximizing Clinical Trial Success

Strategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies
Whitepaper

eConsent: Flexible Consent Through Enabling Technologies

How can eConsent provide a more flexible approach to informed consent?

Whitepaper

The Hematopoietic Colony Forming Cell (CFC) Assay for Drug Safety and Toxicity

The preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process

Whitepaper

Accessing and Analyzing Relevant Content in Today’s Information Chaos – R&D Challenges and Opportunities

We’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing?

Whitepaper

Blueprint for Commercializing Cell and Gene Therapies

How advanced medicines commercial readiness differs and the resources needed to maximize potential.

Whitepaper

Coming to America: Keys to Success for ex-US Digital Health Companies Entering the US Market

This paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market.
Whitepaper

Plan for scalable process liquid and buffer preparation

Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation.

Whitepaper

Running Decentralized Trials at Scale

Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment.
Whitepaper

Key Clinical Supply Issues Sponsors Should Consider with their CRO

As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs.

Whitepaper

Specialized Expertise for Management of Clinical Supply Budgets

For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management.
Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.
Whitepaper

Designing an Optimal APAC Clinical Supply Chain

Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific.
Whitepaper

Roles and Responsibilities of Specialized Clinical Supply Experts

How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis.
Whitepaper

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.
Whitepaper

Questions You Need to Ask Your CRO About Clinical Supply

Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial.
 

Industry Events

 

Upcoming Fierce Events

1-3
May
May 1-3, 2023 | Jersey City, NJ
12-14
Jun
San Diego, CA
13
Jun
Free Virtual Event
20-22
Jun
Free Virtual Event
22
Jun
Free Virtual Event

View all events